Clinical Trial Update: Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of adding primary tumor resection to osimertinib in advanced EGFR-mutant non-small cell lung cancer, which …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Jianxing He | Conditions: Non-Small Cell Lung Cancer, EGFR | Phase 2 | Status: NOT_YET_RECRUITING